Algernon Pharmaceuticals Inc.
AGNPFOTCHealthcare● Active
$0.44
+$0.01(+1.36%)
Market Cap$1541620
P/E Ratio—
52W High$0.713
52W Low$0.23
Algernon Pharmaceuticals Inc. (AGNPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AGNPF · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
-$0.08
Est. -$0.50 · +83.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
AGNPF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 24, 2026 | -$4.97 | — | — | — | — | — |
| ◌ Q2 FY2026 | May 5, 2026 | — | — | — | — | — | — |
| ▲ Q2 FY2026 | Apr 27, 2026 | -$0.50 | -$0.08 | +83.8% | — | — | — |
| — Q1 FY2026 | Jan 29, 2026 | — | -$0.12 | — | — | — | — |
| — Q3 FY2025 | Aug 31, 2025 | — | -$0.01 | — | — | — | — |
| — Q3 FY2025 | Aug 1, 2025 | — | -$0.15 | — | — | — | — |
| — Q2 FY2025 | Apr 29, 2025 | — | -$0.10 | — | — | — | — |
| — Q1 FY2025 | Jan 29, 2025 | — | -$0.10 | — | — | — | — |
Q3 FY2026
Jul 24, 2026
EPS Actual
—
EPS Est.
-$4.97
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.50
EPS Surpr.
+83.8%
Revenue
—
Q1 FY2026
Jan 29, 2026
EPS Actual
-$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 31, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 1, 2025
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 29, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Jan 29, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-1.90 | $-1.90 | $-1.90 | 1 |
| Q3 FY2028 | $-1.36 | $-1.36 | $-1.36 | 1 |
| Q2 FY2028 | $-0.99 | $-0.99 | $-0.99 | 1 |
| Q1 FY2028 | $-1.42 | $-1.42 | $-1.42 | 1 |
| Q4 FY2027 | $-1.56 | $-1.56 | $-1.56 | 1 |
| Q3 FY2027 | $-2.04 | $-2.04 | $-2.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 27, 2026 | +83.8% | $0.31 | $0.27 | -12.81% |
| — Q1 FY2026 | Jan 29, 2026 | — | $0.37 | $0.37 | -1.08% |
| — Q3 FY2025 | Aug 31, 2025 | — | $0.40 | $0.50 | +24.00% |
| — Q3 FY2025 | Aug 1, 2025 | — | $0.47 | $0.47 | +0.00% |
| — Q2 FY2025 | Apr 29, 2025 | — | $0.52 | $0.52 | +0.00% |
| — Q1 FY2025 | Jan 29, 2025 | — | $0.54 | $0.62 | +15.11% |
| — Q3 FY2024 | Aug 31, 2024 | — | $0.80 | $0.77 | -3.38% |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.91 | $0.82 | -9.95% |
Q2 FY2026-12.81%
Report Date
Apr 27, 2026
EPS Beat/Miss
+83.8%
Price Before
$0.31
Price After
$0.27
Q1 FY2026-1.08%
Report Date
Jan 29, 2026
EPS Beat/Miss
—
Price Before
$0.37
Price After
$0.37
Q3 FY2025+24.00%
Report Date
Aug 31, 2025
EPS Beat/Miss
—
Price Before
$0.40
Price After
$0.50
Q3 FY2025+0.00%
Report Date
Aug 1, 2025
EPS Beat/Miss
—
Price Before
$0.47
Price After
$0.47
Q2 FY2025+0.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
—
Price Before
$0.52
Price After
$0.52
Q1 FY2025+15.11%
Report Date
Jan 29, 2025
EPS Beat/Miss
—
Price Before
$0.54
Price After
$0.62
Q3 FY2024-3.38%
Report Date
Aug 31, 2024
EPS Beat/Miss
—
Price Before
$0.80
Price After
$0.77
Q2 FY2024-9.95%
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.91
Price After
$0.82
Avg Beat Reaction-12.81%
Beat Rate1 / 8 quarters
Largest Move+24.00% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AGNPF ends December
Algernon Pharmaceuticals Inc. (AGNPF) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $-0.08 — beating the analyst consensus of $-0.50 by +83.8%. The next AGNPF earnings date is expected around September 2, 2026.
Each quarter, investors track AGNPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AGNPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AGNPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AGNPF earnings · 5 questionsAlgernon Pharmaceuticals Inc.'s next earnings report is expected around September 2, 2026. AGNPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AGNPF historically reports after market close (AMC).
AGNPF earnings datewhen is AGNPF earningsAGNPF next earnings datewhen does AGNPF report earningsAGNPF earnings calendar
▸ Source: FMP · Algernon Pharmaceuticals Inc. SEC filings · US GAAP · Algernon Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026